Clinixir, Thailand’s leading Contract Research Organization (CRO), is pleased to share progress on a Phase II/III clinical trial investigating a potential immunotherapy for advanced hepatocellular carcinoma. This randomized, controlled study aims to enroll 150 patients across sites in Thailand and Malaysia. Clinixir’s role has focused on activating sites, coordinating patient recruitment, and supporting study milestones, advancing the trial’s success and contributing significantly to its overall progress. With nine clinical sites now active across both countries, enrollment is steadily progressing, with patient enrollment anticipated to conclude by mid-2025.